AJP - Endocrinology and Metabolism, Vol 272, Issue 3 E352-E358, Copyright © 1997 by American Physiological Society

ARTICLES

IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF-I infusion rates

N. Porksen, M. A. Hussain, T. L. Bianda, B. Nyholm, J. S. Christiansen, P. C. Butler, J. D. Veldhuis, E. R. Froesch and O. Schmitz
Department of Endocrinology and Metabolism M, Aarhus University Hospital, Denmark.

Insulin-like growth factor I (IGF-I) shares structural and functional features with insulin, affects carbohydrate metabolism, and inhibits insulin secretion. Insulin secretion is pulsatile, and it is regulated by changing frequency and/or mass of secretory bursts. To examine the mechanism of IGF-I's inhibition of insulin secretion, eight healthy volunteers were studied three times. During glucose infusion (2.5 mg x kg(-1) x min(-1)) blood was sampled minutely at time 75-200 min for triplicate insulin concentration measurements by enzyme-linked immunosorbent assay (ELISA; coefficient of variation 2.1%). Time 125 min infusion of saline, low-dose IGF-I (0.025 microg x kg(-1) x min(-1)) or high-dose IGF-I (0.15 microg x kg(-1) x min(-1)) was commenced and continued until 200 min. Data were compared before (75-125 min) vs. during infusion (150-200 min). Insulin concentration time series were deconvolved, using validated pulse-detection criteria, to assess insulin secretory burst mass and frequency. During saline infusion no time effect occurred. After IGF-I infusion, serum C-peptide decreased (582 +/- 85 vs. 481 +/- 82 pM, low-dose IGF-I, P < 0.05; 539 +/- 84 vs. 427 +/- 69 pM, high-dose IGF-I, P < 0.01). Total insulin secretion rates decreased by 17 and 21%, respectively, via specific inhibition of the insulin secretory burst mass (31 +/- 8 vs. 20 +/- 4 pmol/ml, low-dose IGF-I, P = 0.06; 22 +/- 4 vs. 17 +/- 3 pmol/ml, high-dose IGF-I, P < 0.05), whereas the frequency was not affected (10.5 +/- 1.3 vs. 10.7 +/- 1.3 pulses/h, low-dose IGF-I, P = 0.85; 8.7 +/- 1.0 vs. 11.1 +/- 1.2 min/pulse, high-dose IGF-I, P = 0.15). We conclude that IGF-I inhibits pulsatile insulin secretion by specific inhibition of mass but not frequency of secretory bursts.

This article has been cited by other articles:

				N. Porksen, T. Grofte, J. Greisen, A. Mengel, C. Juhl, J. D. Veldhuis, O. Schmitz, M. Rossle, and H. Vilstrup Human insulin release processes measured by intraportal sampling Am J Physiol Endocrinol Metab, March 1, 2002; 282(3): E695 - E702. [Abstract] [Full Text] [PDF]

				N. Porksen, M. Hollingdal, C. Juhl, P. Butler, J. D. Veldhuis, and O. Schmitz Pulsatile Insulin Secretion: Detection, Regulation, and Role in Diabetes Diabetes, February 1, 2002; 51(90001): S245 - 254. [Abstract] [Full Text] [PDF]

				C. B. Juhl, N. Porksen, S. M. Pincus, A. P. Hansen, J. D. Veldhuis, and O. Schmitz Acute and Short-Term Administration of a Sulfonylurea (Gliclazide) Increases Pulsatile Insulin Secretion in Type 2 Diabetes Diabetes, August 1, 2001; 50(8): 1778 - 1784. [Abstract] [Full Text] [PDF]

				N. Porksen, C. Juhl, M. Hollingdal, S. M. Pincus, J. Sturis, J. D. Veldhuis, and O. Schmitz Concordant induction of rapid in vivo pulsatile insulin secretion by recurrent punctuated glucose infusions Am J Physiol Endocrinol Metab, January 1, 2000; 278(1): E162 - E170. [Abstract] [Full Text] [PDF]